abrdn Income Credit Strategies ACP Pharma — Liabilities And Stockholders Equity
Other segment segments
Other financials
Where this comes from
Reported directly by abrdn Income Credit Strategies in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.
The official record: abrdn Income Credit Strategies’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about abrdn Income Credit Strategies's pharma — liabilities and stockholders equity.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is abrdn Income Credit Strategies's pharma — liabilities and stockholders equity?
- abrdn Income Credit Strategies (ACP) reported pharma — liabilities and stockholders equity of $222M in Q1 2026.
- How has abrdn Income Credit Strategies's pharma — liabilities and stockholders equity changed year-over-year?
- abrdn Income Credit Strategies's pharma — liabilities and stockholders equity decreased by 19.0% year-over-year, from $274M to $222M.
- What is the long-term trend for abrdn Income Credit Strategies's pharma — liabilities and stockholders equity?
- Over 4 years (2021 to 2025), abrdn Income Credit Strategies's pharma — liabilities and stockholders equity has grown at a -5.4% compound annual growth rate (CAGR), from $1.26B to $1.01B.
- What does pharma — liabilities and stockholders equity mean?
- The total sum of all liabilities and equity accounts for the pharmaceutical segment, which must equal the segment's total assets. This metric represents the total capital structure and financing sources utilized by the business. It is a fundamental balance sheet figure used to verify the accounting integrity of the segment's financial reporting.